Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:GRCE

Grace Therapeutics Q3 2026 Earnings Report

Grace Therapeutics logo
$2.33 -0.03 (-1.27%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$2.33 +0.00 (+0.17%)
As of 05/5/2026 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Grace Therapeutics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q3 2026
Date
2/12/2026
Time
Before Market Opens
Conference Call Date
Thursday, February 12, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Grace Therapeutics' Q4 2026 earnings is estimated for Monday, June 22, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, June 23, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Grace Therapeutics' Q3 2026 Press ReleasePress Release
(8-K)
Grace Therapeutics' Q3 2026 Quarterly reportQuarterly report
(10-Q)

Grace Therapeutics Earnings Headlines

Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/grace-therapeutics-grce-price-target-decreased-by-47-83-to-6-12/ar-AA21Sccg
FDA declines Grace's stroke drug over manufacturing and packaging issues, shares slump
April 25, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/fda-declines-graces-stroke-drug-over-manufacturing-and-packaging-issues-shares-slump/ar-AA21AAfL
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
 |  Weiss Ratings (Ad)
Grace Therapeutics Shares Fall After FDA Flags Issues in Aneurysm Treatment Application
April 23, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/grace-therapeutics-shares-fall-after-fda-flags-issues-in-aneurysm-treatment-application-9419115d
FDA declines Grace's stroke drug over manufacturing and packaging issues
April 23, 2026  |  msn.comhttps://www.msn.com/en-ca/health/other/fda-declines-graces-stroke-drug-over-manufacturing-and-packaging-issues/ar-AA21zIqw
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
April 23, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/us-fda-declines-approve-grace-therapeutics-drug-type-stroke-2026-04-23/
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways.

Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.

View Grace Therapeutics Profile
Earnings Tools